Logo image of NLSP

NLS PHARMACEUTICS LTD (NLSP) Stock Fundamental Analysis

NASDAQ:NLSP - Nasdaq - CH1384053976 - Common Stock - Currency: USD

1.5  +0.03 (+1.9%)

Premarket: 1.46 -0.04 (-2.67%)

Fundamental Rating

1

NLSP gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NLSP have multiple concerns. NLSP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year NLSP has reported negative net income.
NLSP had a negative operating cash flow in the past year.
NLSP had negative earnings in each of the past 5 years.
In the past 5 years NLSP always reported negative operating cash flow.
NLSP Yearly Net Income VS EBIT VS OCF VS FCFNLSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

The Return On Assets of NLSP (-552.58%) is worse than 94.44% of its industry peers.
Industry RankSector Rank
ROA -552.58%
ROE N/A
ROIC N/A
ROA(3y)-348.14%
ROA(5y)-411.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NLSP Yearly ROA, ROE, ROICNLSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NLSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NLSP Yearly Profit, Operating, Gross MarginsNLSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, NLSP has less shares outstanding
NLSP has less shares outstanding than it did 5 years ago.
NLSP has a worse debt/assets ratio than last year.
NLSP Yearly Shares OutstandingNLSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
NLSP Yearly Total Debt VS Total AssetsNLSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -108.78, we must say that NLSP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NLSP (-108.78) is worse than 93.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -108.78
ROIC/WACCN/A
WACCN/A
NLSP Yearly LT Debt VS Equity VS FCFNLSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 0.15 indicates that NLSP may have some problems paying its short term obligations.
The Current ratio of NLSP (0.15) is worse than 94.95% of its industry peers.
A Quick Ratio of 0.15 indicates that NLSP may have some problems paying its short term obligations.
With a Quick ratio value of 0.15, NLSP is not doing good in the industry: 94.44% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
NLSP Yearly Current Assets VS Current LiabilitesNLSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

1

3. Growth

3.1 Past

NLSP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.12%, which is quite good.
EPS 1Y (TTM)19.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NLSP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.37% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.47%
EPS Next 2Y40.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NLSP Yearly EPS VS EstimatesNLSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -5 -10 -15 -20

1

4. Valuation

4.1 Price/Earnings Ratio

NLSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NLSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NLSP Price Earnings VS Forward Price EarningsNLSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NLSP Per share dataNLSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as NLSP's earnings are expected to grow with 40.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.37%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for NLSP!.
Industry RankSector Rank
Dividend Yield N/A

NLS PHARMACEUTICS LTD

NASDAQ:NLSP (5/1/2025, 9:20:41 PM)

Premarket: 1.46 -0.04 (-2.67%)

1.5

+0.03 (+1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners13.04%
Inst Owner Change0%
Ins Owners24.77%
Ins Owner ChangeN/A
Market Cap2.97M
Analysts43.33
Price TargetN/A
Short Float %2.22%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.72
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-1.98
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS0
BVpS-4.68
TBVpS-4.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -552.58%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-348.14%
ROA(5y)-411.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -108.78
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)133.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.66%
EPS Next Y89.47%
EPS Next 2Y40.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.58%
OCF growth 3YN/A
OCF growth 5YN/A